2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and…

By Jose Luis Zamorano, P. Lancellotti, D. Rodríguez Muñoz, V. Aboyans, R. Asteggiano, M. Galderisi, G. Habib, D. Lenihan, Gregory Y. H. Lip, A. Lyon and 6 more. European Heart Journal, 2016

2,566 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/8e66299909458b766c00c500bf15d2f91a45ab19

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. G. Gulati
2. J. Schulz-Menger
3. S. Heck
4. A. H. Ree
5. P. Hoffmann
6. F. von Knobelsdorff-Brenkenhoff
7. J. Geisler
8. H. Røsjø

Citations in the corpus

• Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol (2016, background): “Population: Different lymphomas Echo (12) There was no significant difference in the change in LVEF between the control and the intervention group”